Form 4: Cidara Therapeutics Director Acquires Stock Options Under RA Capital Arrangement

Director Laura Tadvalkar acquired 4,250 stock options in Cidara Therapeutics, but disclaims beneficial ownership due to an arrangement with RA Capital Management.

Summary

• On April 26, 2024, Laura Tadvalkar, a director of Cidara Therapeutics, Inc., acquired 4,250 stock options with an exercise price of $12.63.
• The options vest over a three-year period, with one-third vesting on April 26, 2025, and the remainder vesting in equal monthly installments over the following two years, completing on April 26, 2027.
• Tadvalkar holds these options for the benefit of RA Capital Healthcare Fund, L.P., and will transfer any proceeds to RA Capital Management, L.P. to offset advisory fees.
• Due to this arrangement, Tadvalkar disclaims beneficial ownership of the options and the underlying common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reports a transaction without expressing any positive or negative outlook.

Industry Context

This filing reflects standard practice for reporting changes in beneficial ownership by company insiders, particularly directors, and is a routine part of regulatory compliance.

Related Party Transactions

• The arrangement between Laura Tadvalkar, RA Capital Management, L.P., and RA Capital Healthcare Fund, L.P. constitutes a related party transaction, where Tadvalkar holds the options for the benefit of the fund and will transfer proceeds to offset advisory fees.

Stakeholder Impact

• The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially impacting shareholder sentiment positively.
• However, the disclaimed beneficial ownership due to the RA Capital arrangement may temper this effect.

Key Dates